Limits...
Impact of interleukin-6 promoter polymorphism and serum interleukin-6 level on the acute inflammation and neovascularization stages of patients with Eales' disease.

Sen A, Paine SK, Chowdhury IH, Mukherjee A, Choudhuri S, Saha A, Mandal LK, Bhattacharya B - Mol. Vis. (2011)

Bottom Line: Serum IL-6 also significantly correlated with hsCRP (Spearman's correlation coefficient; r=0.4992, p=0.0009), but not with VEGF in this stage in ED patients.A statistically significant association was found between the -174GG genotype (p=0.006) and occurrence of ED.IL-6 expression, regulated by the allelic distribution of -174 loci and the enhanced level of IL-6, modulates CRP and VEGF concentration depending respectively on the acute inflammatory stimulation at the initial stage and angiogenic stimulation at the advanced stage of ED.

View Article: PubMed Central - PubMed

Affiliation: Department of Biochemistry, Dr. B C Roy Post Graduate Institute of Basic Medical Education and Research (IPGME&R), Kolkata, India.

ABSTRACT

Purpose: To evaluate the role of interleukin-6 (IL-6) in the inflammatory and proliferative stages of Eales' disease (ED) and to determine the influence of IL-6-174G/C polymorphism in the IL-6 and IL-6-regulated protein expression, as well as the development of ED.

Methods: One hundred and twenty-one patients diagnosed with ED, 223 matched healthy controls, and 16 control patients with macular holes were recruited from the eastern Indian population. Serum and vitreous levels of IL-6 and vascular endothelial growth factors (VEGF) were measured by enzyme-linked immunosorbent assay. Serum levels of high-sensitivity C-reactive protein (hsCRP) were measured by enzyme immunoassay. Subjects were genotyped for the IL-6-174G/C polymorphism (rs1800795) by a custom TaqMan single-nucleotide polymorphism (SNP) Genotyping Assays system.

Results: Serum IL-6 (p<0.0001), hsCRP (p<0.0001), and VEGF (p=0.0031) levels were significantly higher in the inflammatory stage of ED than in healthy controls. Serum IL-6 also significantly correlated with hsCRP (Spearman's correlation coefficient; r=0.4992, p=0.0009), but not with VEGF in this stage in ED patients. At the proliferative stage of ED, significantly higher levels of vitreous IL-6 (p=<0.0001) and VEGF (p=<0.0001) were found compared with the vitreous of patients with macular holes. A significant correlation was observed between vitreous IL-6 and VEGF in ED patients (Spearman's correlation coefficient; r=0.5834, p=0.0087). A statistically significant association was found between the -174GG genotype (p=0.006) and occurrence of ED. Mean serum and vitreous concentrations of IL-6 were also higher in the subjects with the GG genotype than in those with the GC or CC genotype in this population.

Conclusions: IL-6 expression, regulated by the allelic distribution of -174 loci and the enhanced level of IL-6, modulates CRP and VEGF concentration depending respectively on the acute inflammatory stimulation at the initial stage and angiogenic stimulation at the advanced stage of ED.

Show MeSH

Related in: MedlinePlus

Correlation between vitreous levels of interleukin-6 and vascular endothelial growth factor from 19 patients with Eales’ disease in the proliferative stage. The interleukin-6 (IL-6) levels in vitreous were correlated significantly with vitreous vascular endothelial growth factor (VEGF) levels (Spearman’s correlation coefficient; r=0.5834, p=0.0087). The solid line represents the linear regression curve of the best fit.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3198485&req=5

f2: Correlation between vitreous levels of interleukin-6 and vascular endothelial growth factor from 19 patients with Eales’ disease in the proliferative stage. The interleukin-6 (IL-6) levels in vitreous were correlated significantly with vitreous vascular endothelial growth factor (VEGF) levels (Spearman’s correlation coefficient; r=0.5834, p=0.0087). The solid line represents the linear regression curve of the best fit.

Mentions: There was no significant correlation between the vitreous and serum levels of IL-6 (Spearman’s correlation coefficient; r=0.2789, p=0.2475) and the vitreous and serum levels of VEGF (Spearman’s correlation coefficient; r=0.2045, p=0.4009) in patients in the proliferative stage of ED. Vitreous concentrations of VEGF and IL-6 were significantly higher than that obtained from the serum of ED patients (1058.3 pg/ml versus 324.96 pg/ml; p=0.0001 and 79.8 pg/ml versus 2.017 pg/ml; p<0.0001). However, a statistically significant directly proportional dependence was found between vitreous concentration of IL-6 and VEGF (Spearman’s correlation coefficient; r=0.5834, p=0.0087) in ED patients (Figure 2).


Impact of interleukin-6 promoter polymorphism and serum interleukin-6 level on the acute inflammation and neovascularization stages of patients with Eales' disease.

Sen A, Paine SK, Chowdhury IH, Mukherjee A, Choudhuri S, Saha A, Mandal LK, Bhattacharya B - Mol. Vis. (2011)

Correlation between vitreous levels of interleukin-6 and vascular endothelial growth factor from 19 patients with Eales’ disease in the proliferative stage. The interleukin-6 (IL-6) levels in vitreous were correlated significantly with vitreous vascular endothelial growth factor (VEGF) levels (Spearman’s correlation coefficient; r=0.5834, p=0.0087). The solid line represents the linear regression curve of the best fit.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3198485&req=5

f2: Correlation between vitreous levels of interleukin-6 and vascular endothelial growth factor from 19 patients with Eales’ disease in the proliferative stage. The interleukin-6 (IL-6) levels in vitreous were correlated significantly with vitreous vascular endothelial growth factor (VEGF) levels (Spearman’s correlation coefficient; r=0.5834, p=0.0087). The solid line represents the linear regression curve of the best fit.
Mentions: There was no significant correlation between the vitreous and serum levels of IL-6 (Spearman’s correlation coefficient; r=0.2789, p=0.2475) and the vitreous and serum levels of VEGF (Spearman’s correlation coefficient; r=0.2045, p=0.4009) in patients in the proliferative stage of ED. Vitreous concentrations of VEGF and IL-6 were significantly higher than that obtained from the serum of ED patients (1058.3 pg/ml versus 324.96 pg/ml; p=0.0001 and 79.8 pg/ml versus 2.017 pg/ml; p<0.0001). However, a statistically significant directly proportional dependence was found between vitreous concentration of IL-6 and VEGF (Spearman’s correlation coefficient; r=0.5834, p=0.0087) in ED patients (Figure 2).

Bottom Line: Serum IL-6 also significantly correlated with hsCRP (Spearman's correlation coefficient; r=0.4992, p=0.0009), but not with VEGF in this stage in ED patients.A statistically significant association was found between the -174GG genotype (p=0.006) and occurrence of ED.IL-6 expression, regulated by the allelic distribution of -174 loci and the enhanced level of IL-6, modulates CRP and VEGF concentration depending respectively on the acute inflammatory stimulation at the initial stage and angiogenic stimulation at the advanced stage of ED.

View Article: PubMed Central - PubMed

Affiliation: Department of Biochemistry, Dr. B C Roy Post Graduate Institute of Basic Medical Education and Research (IPGME&R), Kolkata, India.

ABSTRACT

Purpose: To evaluate the role of interleukin-6 (IL-6) in the inflammatory and proliferative stages of Eales' disease (ED) and to determine the influence of IL-6-174G/C polymorphism in the IL-6 and IL-6-regulated protein expression, as well as the development of ED.

Methods: One hundred and twenty-one patients diagnosed with ED, 223 matched healthy controls, and 16 control patients with macular holes were recruited from the eastern Indian population. Serum and vitreous levels of IL-6 and vascular endothelial growth factors (VEGF) were measured by enzyme-linked immunosorbent assay. Serum levels of high-sensitivity C-reactive protein (hsCRP) were measured by enzyme immunoassay. Subjects were genotyped for the IL-6-174G/C polymorphism (rs1800795) by a custom TaqMan single-nucleotide polymorphism (SNP) Genotyping Assays system.

Results: Serum IL-6 (p<0.0001), hsCRP (p<0.0001), and VEGF (p=0.0031) levels were significantly higher in the inflammatory stage of ED than in healthy controls. Serum IL-6 also significantly correlated with hsCRP (Spearman's correlation coefficient; r=0.4992, p=0.0009), but not with VEGF in this stage in ED patients. At the proliferative stage of ED, significantly higher levels of vitreous IL-6 (p=<0.0001) and VEGF (p=<0.0001) were found compared with the vitreous of patients with macular holes. A significant correlation was observed between vitreous IL-6 and VEGF in ED patients (Spearman's correlation coefficient; r=0.5834, p=0.0087). A statistically significant association was found between the -174GG genotype (p=0.006) and occurrence of ED. Mean serum and vitreous concentrations of IL-6 were also higher in the subjects with the GG genotype than in those with the GC or CC genotype in this population.

Conclusions: IL-6 expression, regulated by the allelic distribution of -174 loci and the enhanced level of IL-6, modulates CRP and VEGF concentration depending respectively on the acute inflammatory stimulation at the initial stage and angiogenic stimulation at the advanced stage of ED.

Show MeSH
Related in: MedlinePlus